en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
3/2006
vol. 44
 
Share:
Share:
more
 
 
abstract:

Original paper
Early outcome of patients with rheumatoid arthritis treated with infliximab

Aleksandra Zoń-Giebel
,
Wiesława Liwoch-Morżoł
,
Janina Witkowska-Tomiczek
,
Andrzej Banasik
,
Piotr Sikora
,
Eugeniusz Zielonka
,
Danuta Kapołka

RU 2006; 44, 3: 128–133
Online publish date: 2006/06/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The aim of this study was to analyse the outcome of patients with rheumatoid arthritis (RA) treated with infliximab. Thirty-one patients (3 male, 28 female), aged 50 years (range 22-67 years), treated in a single institution between 2001-2003 were included. For the purpose of this study, RA activity was analysed at baseline, after 23 weeks (i.e. after 5 infusions), and after 54 weeks (i.e. after 9 infusions). Twenty-one (68%) patients achieved good response according to EULAR criteria after both 23 and 54 weeks of therapy. None of the patients who failed to respond after 23 weeks responded after 54 weeks. None of the analysed factors (age, sex, disease duration, number of preceding disease-modifying anti-rheumatic drugs) was found to influence the probability to achieve good response. Our results indicate high efficacy of infliximab in the treatment of RA. They also suggest that the treatment protocol could further be rationalised.
keywords:

infliximab, rheumatoid arthritis







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.